Loading...
TNGX logo

Tango Therapeutics, Inc.NasdaqGM:TNGX 주식 보고서

시가총액 US$3.4b
주가
US$23.02
US$23.9
3.7% 저평가 내재 할인율
1Y2,034.5%
7D8.6%
포트폴리오 가치
​
보기

Tango Therapeutics, Inc.

NasdaqGM:TNGX 주식 리포트

시가총액: US$3.4b

Tango Therapeutics (TNGX) 주식 개요

정밀 종양학 회사인 탱고 테라퓨틱스는 미충족 의료 수요가 있는 특정 환자군을 대상으로 약물을 발견하고 개발하는 데 주력하고 있습니다. 자세히 보기

TNGX 펀더멘털 분석
스노우플레이크 점수
가치 평가0/6
미래 성장2/6
과거 실적0/6
재무 건전성6/6
배당0/6

강점

수익은 연간 56.64% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 3개월 동안 주가 변동성이 US 시장과 비교해 높았습니다.


TNGX Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
Pharmaceuticals & Biotech opportunity
GANX logo
Gain Therapeutics
Fair Value from
US$7.675.4% 저평가 내재 할인율

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.

Read full narrative
Read narrative

Tango Therapeutics, Inc. 경쟁사

가격 이력 및 성과

Tango Therapeutics 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$23.48
52주 최고가US$28.41
52주 최저가US$1.03
베타1.22
1개월 변동18.59%
3개월 변동87.69%
1년 변동2,034.55%
3년 변동534.59%
5년 변동107.79%
IPO 이후 변동129.52%

최근 뉴스 및 업데이트

분석 기사 • Jan 19

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders have had their patience rewarded with a 53% share price jump in...

Recent updates

분석 기사 • Jan 19

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders have had their patience rewarded with a 53% share price jump in...
분석 기사 • Dec 05

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%

Despite an already strong run, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have been powering on, with a gain of...
Seeking Alpha • Nov 21

Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy

Summary Tango Therapeutics, Inc. is initiated with a Buy rating due to strong progress with its lead PRMT5 inhibitor, vopimetostat, for MTAP-deleted cancers. TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus historical controls. A pivotal trial for vopimetostat in 2nd-line MTAP-deleted pancreatic cancer patients is set for 2026, with additional combination and expansion studies planned for broader indications. There is an expansion opportunity as vopimetostat is also being explored in a study targeting MTAP-deleted lung cancer patients, with data expected to be released in 2026. Read the full article on Seeking Alpha
분석 기사 • Sep 17

Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected

With a price-to-sales (or "P/S") ratio of 33.7x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be sending very bearish...
분석 기사 • May 15

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results

The analysts might have been a bit too bullish on Tango Therapeutics, Inc. ( NASDAQ:TNGX ), given that the company fell...
분석 기사 • Apr 14

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 28% in the last...
분석 기사 • Apr 04

Here's Why We're Watching Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
분석 기사 • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Not Doing Enough For Some Investors As Its Shares Slump 30%

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Seeking Alpha • Jan 23

Tango Therapeutics: Chance For A Short Squeeze

Summary Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulation and positive momentum for TNGX. I decided to buy OTM call options on TNGX due to the low implied volatility. Read the full article on Seeking Alpha
분석 기사 • Dec 05

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Oct 31

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 26% in the last...
Seeking Alpha • Sep 10

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Summary Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts. Despite the high risk, Tango's differentiated approach and potential blockbuster candidates make TNGX stock an intriguing speculative buy ahead of critical data readouts. Read the full article on Seeking Alpha
분석 기사 • Sep 01

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have continued their recent momentum with a 29% gain in the last month...
분석 기사 • Jun 29

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a really impressive month, gaining 27% after a shaky period...
분석 기사 • May 30

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Key Insights Tango Therapeutics will host its Annual General Meeting on 5th of June Salary of US$626.0k is part of CEO...
분석 기사 • Mar 19

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a horrible month, losing 30% after a relatively good period...
분석 기사 • Mar 06

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tango Therapeutics...
분석 기사 • Jan 08

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

You may think that with a price-to-sales (or "P/S") ratio of 25x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) is a stock to...
분석 기사 • Nov 09

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Shareholders in Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be thrilled to learn that the analysts have just delivered...
분석 기사 • Aug 12

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders will have a reason to smile today, with the analysts making...
분석 기사 • May 10

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 20

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

H.C. Wainwright has started Tango Therapeutics (NASDAQ:TNGX) with a buy rating citing its use of synthetic lethality to develop cancer candidates. The firm has a $10 price target (~43% upside based on Wednesday's close). Analyst Robert Burns said that the targets the company is focused on could potentially treat large patient populations. He cited TNG908, Tango's (TNGX) most advanced candidate, currently in phase 1/2 for MTAP-deleted tumors. Initial data is expected in H1 2023. After determining the optimum dose for TNG908, Tango (TNGX) says it will evaluate efficacy in multiple tumor types in specific cohorts, including malignant peripheral nerve sheath tumor, non-small cell lung cancer, mesothelioma, cholangiocarcinoma, and glioblastoma. Seeking Alpha's Quant Rating views Tango (TNGX) as a buy with high marks for growth and momentum.
분석 기사 • Oct 05

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
분석 기사 • Aug 13

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

The investors in Tango Therapeutics, Inc. 's ( NASDAQ:TNGX ) will be rubbing their hands together with glee today...
Seeking Alpha • Aug 10

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Tango Therapeutics press release (NASDAQ:TNGX): Q2 GAAP EPS of -$0.28 beats by $0.03. Revenue of $5.78M (-68.2% Y/Y) beats by $0.12M.
분석 기사 • May 28

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Jan 06

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

주주 수익률

TNGXUS BiotechsUS 시장
7D8.6%1.2%2.1%
1Y2,034.5%41.9%30.6%

수익률 대 산업: TNGX은 지난 1년 동안 41.9%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: TNGX은 지난 1년 동안 30.6%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is TNGX's price volatile compared to industry and market?
TNGX volatility
TNGX Average Weekly Movement14.0%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

안정적인 주가: TNGX의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.

시간에 따른 변동성: TNGX의 주간 변동성(14%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.

회사 소개

설립직원 수CEO웹사이트
2017137Malte Peterswww.tangotx.com

정밀 종양학 회사인 탱고 테라퓨틱스는 미충족 의료 수요가 있는 특정 환자군을 대상으로 약물을 발견하고 개발하는 데 주력하고 있습니다. 회사는 췌장암 및 폐암 치료를 위한 임상 1/2상 시험 중인 TNG462와 교모세포종 치료를 위한 뇌 침투성 PRMT5 억제제인 TNG456을 포함한 메틸티오아데노신-협조 단백질 아르기닌 메틸전달효소 5(PRMT5) 억제제를 개발합니다. 폐암 치료를 위해 세린-트레오닌 키나아제(STK) 11 기능 상실 돌연변이의 면역 회피 효과를 역전시키는 리프레서 요소-1 침묵 전사 억제제인 TNG260을 개발 중입니다.

Tango Therapeutics, Inc. 기초 지표 요약

Tango Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
TNGX 기초 통계
시가총액US$3.41b
순이익 (TTM)-US$101.59m
매출 (TTM)US$62.38m
54.3x
주가매출비율(P/S)
-33.3x
주가수익비율(P/E)

TNGX는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
TNGX 손익계산서 (TTM)
매출US$62.38m
매출원가US$132.17m
총이익-US$69.78m
기타 비용US$31.81m
순이익-US$101.59m

최근 보고된 실적

Dec 31, 2025

다음 실적 발표일

해당 없음

주당순이익(EPS)-0.70
총이익률-111.86%
순이익률-162.85%
부채/자본 비율0%

TNGX의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/07 03:45
종가2026/05/07 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Tango Therapeutics, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Yuan ZhiB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Eric SchmidtCantor Fitzgerald & Co.